Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.
We investigated the relationships between common polymorphisms in CYP1A2 (CYP1A2(⁎)1C and (⁎)1F), CYP1A2-mRNA levels in circulating lymphocytes and clozapine(CLZ)-induced adverse drug reactions (ADRs) in 34 patients. Patients with ADRs had a higher frequency of CYP1A2 low activity allele combinations (8/12; 67%) and lower CYP1A2-mRNA levels than patients without ADRs (6/22; 27%, P=0.019).
Department of Clinical Medicine- Section Clinical and Experimental Pharmacology, University of Insubria, Via Otorino Rossi 9, 21100 Varese, Italy.
Marco
M
Ferrari
Emilio
E
Bolla
Paola
P
Bortolaso
Camilla
C
Callegari
Nicola
N
Poloni
Sergio
S
Lecchini
Simone
S
Vender
Franca
F
Marino
Marco
M
Cosentino
D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics*
D014150:Antipsychotic Agents; C504573:CYP1A2 protein, human; D019388:Cytochrome P-450 CYP1A2; D003024:Clozapine